Search

Fluoride represents an essential element in dental development and safety. Fluoride deficiency is associated with dental cavities. The main dietary source of fluoride is in water, followed by fluoridated toothpaste, tea, seafood, canned sardines or shells as well as medicinal supplements. The adequate intake ranges from 0.7 mg/day for toddlers, to 3 mg/day for adult females and 4 mg/day for adult males. The fluoride intake can present a difficulty in assessment, especially during pregnancy, so the question remains: is fluoride supplementation recommended during pregnancy to prevent dental cavities in the offspring? The correct answer is ‘No’. Fluoride supplementation during pregnancy does not reduce the incidence of caries in offspring. Centers for Disease Control and Prevention (CDC) does not recommend fluoride supplementation due to its action mechanism; fluoride has beneficial effects only after the tooth eruption takes place through a topical mechanism. Fluorosis (fluoride toxicity) in offspring has not been described secondary to excessive ingestion of fluoride of the mother during pregnancy, but there are studies correlating neurotoxic effects in the infants from mothers who received fluoride supplementation.

Prenatal ultrasound examination should take place between 18 and 20 week of gestation and is important for early detection of fetal anomalies such as the facial malformations. One important anatomic element is the palate that raises echographic technical difficulties such as the shadowing by facial bones and, especially, by the superior alveolar ridge, the fetal prone position and its localization, respectively, profoundly, inside of fetal head or anatomic obstacles such as the fetal tongue, so new echographic examination techniques are being under evaluation. The prenatal detection rate of fetal cleft palate remains low, so various methods of examination are being proposed. The ultrasound assessment of the fetal face is made by 2D ultrasound, technique completed by 3D ultrasound, which includes the evaluation in both axial and coronal planes, with the uvula being analyzed in two types of section, transversal and sagittal. In the latter to epiglottis is a landmark that confirms the identification of the uvula and a normal uvula has a typical and resembling echographic pattern to the equal sign. Even though prenatal diagnosis of soft palate cleft is a real challenge, with low detection rate due to difficulty of its visualization during routine examination, and even if suspected, diagnostic accuracy is low.

Hemivertebra is a common cause of congenital scoliosis and results from a lack of formation of one-half of the vertebral body. This condition is very rare and can present as solitary or as a syndrome component: i.e., the split notochord syndrome, which often implies vertebral defects, from a bifid vertebra to hemivertebrae, or fused vertebrae. We describe a case of supernumerary lateral hemivertebra detected prenatally at 12 weeks of gestation and the ultrasonography specifics that lead to early and accurate diagnosis, monitoring during pregnancy, and follow-up at the 4-year period. The case is presented to specify the importance of an early assessment of fetal spine and diagnosis of various conditions, including hemivertebrae, considering the significant association with other anomalies (cardiovascular, urinary, skeletal, gastrointestinal, and central nervous systems), which are most commonly involved. Moreover, the need to counsel future parents on the risks implied by this anomaly is important for the obstetrician. We underline the inclusion of these types of congenital conditions in high-risk pregnancy because of the frequent association with high cesarean delivery rates, growth restriction, delivery before term, and higher morbidity rates.

Objective: The aim of this study is to propose a standardized management of care for patients diagnosed with cesarean scar pregnancy (CSP). There are two types of CSP: Type 1 (on the scar) vs. type 2 (in the niche). To date there is no international standard to predict the extent of invasion or the optimal management of CSP. Materials and methods: We used intramuscular methotrexate injection followed by uterine artery embolization combined with suction evacuation as a conservative approach for the treatment of seven patients diagnosed with CSP. Our inclusion criteria, to be satisfied simultaneously, were established as follows: (1) patients with CSP; (2) early gestational age ≤ 9 weeks, and (3) written consent of the proposed treatment of the patient. Results: This course of treatment produced a positive outcome in all cases. We did not have any complications (e.g., emergency hysterectomy, perforation of the uterine cavity, severe hemorrhage, or endometritis) during the procedures or in the follow-up. The most important predictors of successful management are early diagnosis of CSP and orientation of the invasive trophoblast opposite to the scar. Conclusions: The main finding from this series of cases is that associating systemic methotrexate and uterine artery embolization provides efficient and low-risk management of CSP. This treatment regime is adequate for both types of CSPs. We consider that early localization diagnosis of pregnancy following a cesarean delivery is mandatory for CSP morbidity prevention.

Neuroendocrine neoplasms (NENs) are particularly rare in all sites of the gynecological tract and include a variety of neoplasms with variable prognosis, dependent on histologic subtype and site of origin. Following the expert consensus proposal of the International Agency for Research on Cancer (IARC), the approach in the latest World Health Organization (WHO) Classification System of the Female Genital Tumours is to use the same terminology for NENs at all body sites. The main concept of this novel classification framework is to align it to all other body sites and make a clear distinction between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The previous WHO Classification System of the Female Genital Tumours featured more or less the same principle, but used the terms ‘low-grade neuroendocrine tumor’ and ‘high-grade neuroendocrine carcinoma’. Regardless of the terminology used, each of these two main categories include two distinct morphological subtypes: NETs are represented by typical and atypical carcinoid and NEC are represented by small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC). High-grade NECs, especially small cell neuroendocrine carcinoma tends to be more frequent in the uterine cervix, followed by the endometrium, while low-grade NETs usually occur in the ovary. NENs of the vulva, vagina and fallopian tube are exceptionally rare, with scattered case reports in the scientific literature.

Cesarean scar defect, niche or isthmocele represents a poor healing in the anterior uterine wall after performing a cesarean section. The cesarean scar defect can be asymptomatic, or the patient could present abnormal uterine bleeding, chronic pelvic pain, dysmenorrhea, dyspareunia, cesarean scar pregnancy or abnormal placenta. Abnormal uterine bleeding caused by cesarean scar defect presents as a postmenstrual spotting and has become more and more common among women with a history of minimum one cesarean section delivery. The most studied risk factors are: multiple cesarean section deliveries, single layer suture, locked suture, retroflexed uterus and cesarean section delivery performed during active labor with a cervical dilatation of 5 cm. There have been described several surgical approaches: hysteroscopic, laparoscopic or vaginal. From our experience, we have treated successfully symptomatic patients with cesarean scar defect with the levonorgestrel-releasing intrauterine system. Although the therapeutic indications do not include this specific use, we have obtained significant improvement of abnormal uterine bleeding due to cesarean scar defect in our patients. Our results sustain the necessity of extensive interventional studies.